Why Austrian Women Are Dying from Silent Heart Disease Symptoms
Why Austrian Women Are Dying from Silent Heart Disease Symptoms
Why Austrian Women Are Dying from Silent Heart Disease Symptoms
Cardiovascular disease remains the top cause of death among women in Austria, claiming over 16,000 lives in 2024 alone. Many women struggle to recognize their symptoms, which often differ from those in men, leading to dangerous delays in diagnosis and treatment.
A new awareness campaign, #GoRedAustria, will launch on February 6 to highlight these gender-specific risks. Organisers are urging people to wear red and post photos on social media with the hashtags #GoRedAustria and #WomensHeartsBeatDifferent.
Experts stress that early prevention and better risk assessments could cut the disease's toll. Yet too often, women dismiss warning signs, mistaking them for less serious issues. The consequences of late diagnoses affect not just individuals but also place a heavier burden on healthcare systems and families.
Unlike typical male symptoms, women may experience subtler signs such as fatigue, nausea, or back pain. These differences make recognition harder, increasing the risk of life-threatening delays in care.
The campaign seeks to close this knowledge gap by educating women about their unique symptoms. With greater awareness, earlier interventions could save lives and reduce the disease's broader impact. Organisers hope the initiative will spark lasting change in how women's heart health is understood and treated.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?